The agreement grants EQGen global rights to Xintela’s stem cell technology for veterinary musculoskeletal indications, including EQSTEM® for horses. Xintela will receive USD 1 million in license fees, USD 3 million worth of EQGen shares, and royalties up to low double digits.

“This is an important validation of Xintela's approach and an opportunity to bring EQSTEM® to the global veterinary market” says Karl Elmqvist, Investment Manager at Flerie.

Read Xintela's full press release here: https://www.xintela.se/en/press-release?slug=xintela-and-eqgen-biomedical-sign-collaboration-and-license-agreement-for-veterinarian-stem-cell-products

Flerie’s holding in Xintela amounts to 61%.

For more information:
Karl Elmqvist
Email: ir@flerie.com

Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com